FLUDARABINE PHOSPHATE, YTB323, CYCLOPHOSPHAMIDE, TOCILIZUMAB
CYTB323M12101B
Phase 2 small_molecule active
Quick answer
FLUDARABINE PHOSPHATE, YTB323, CYCLOPHOSPHAMIDE, TOCILIZUMAB for Difficult to treat rheumatoid arthritis, Severe, refractory Sjogren’s disease with organ involvement is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Difficult to treat rheumatoid arthritis, Severe, refractory Sjogren’s disease with organ involvement
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active